Zdrowie i gospodarka · 18/04/2000
FDA Reopens Comment Period for Proposed Standards for Allogeneic Peripheral and Placental/Umbilical Cord Blood Hematopoietic Stem/Progenitor Cell Products
The FDA is extending the comment period for proposed product standards for unrelated allogeneic peripheral and placental/umbilical cord blood hematopoietic stem/progenitor cells for 90 days, following a request for an extension and allowing more time for review and comment submission.